ExQor Technologies

Executive Summary

ExQor Technologies is a private biotechnology company headquartered in San Diego, focused on developing a unified brain regenerative medicine platform for Alzheimer's disease. Founded in 2015, the company is currently in IND-enabling studies and preparing for first-in-human clinical trials. ExQor's integrated approach combines a proprietary diagnostic MRI contrast agent with a targeted therapeutic biologic, guided by an AI-driven software platform. This multi-modal strategy aims to enable precise early diagnosis and treatment that can reverse neurological damage caused by Alzheimer's, addressing a critical unmet need in neurodegenerative disease. The platform's novelty lies in its convergence of diagnostics, therapeutics, and artificial intelligence to create a closed-loop system for personalized brain repair. As a pre-clinical stage company, ExQor has not yet publicly disclosed funding details or valuation, but its innovative platform positions it as a potential leader in the emerging field of brain regenerative medicine. The company's progress through IND-enabling studies suggests it is nearing a significant inflection point as it transitions from preclinical development to clinical-stage testing, which could unlock substantial value for investors.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Alzheimer's Candidate70% success
• Q1 2027First-in-Human Trial Initiation60% success
• Q2 2026Publication of Preclinical Data in Peer-Reviewed Journal85% success